Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD3 | Q9NY59 | 3/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 9/20 | 0.34 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | CHUK | O15111 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | SCD | O00767 | 2/20 | 0.30 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.30 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL6068862 | 0.99 | SMPD3 (0.38) | SMPD3AOC3CNR2CDK1CDK2 | |
| Bromide SCHEMBL6068466 | 0.99 | SMPD3 (0.38) | SMPD3AOC3CNR2CDK1CDK2 | |
| SCHEMBL6068593 | 0.85 | SIGMAR1 (0.40) | SMPD3 | |
| SCHEMBL6068715 | 0.82 | CNR2 (0.38) | SMPD3AOC3CNR2LRRK2 | |
| SCHEMBL12943112 | 0.72 | SIGMAR1 (0.32) | CNR2 | |
| SCHEMBL5439394 | 0.70 | CYP3A4 (0.38) | SMPD3 | |
| SCHEMBL33881 | 0.69 | CYP1A2 (0.42) | — | |
| SCHEMBL6068622 | 0.69 | PDPK1 (0.36) | SMPD3AOC3CNR2LRRK2 | |
| SCHEMBL14801000 | 0.69 | PIM1 (0.51) | SMPD3 | |
| Hydrochloric Acid SCHEMBL19549166 | 0.68 | CYP1A2 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7091350-B2 | Diaminopyrazole derivatives and their use for oxidation dyeing of keratinous fibres | L'OREAL (FR) | 2006-08-15 | — | — | US | disclosed |
| US-20040088802-A1 | Diaminopyrazole derivatives and their use for oxidation dyeing of keratinous fibres | L'OREAL S.A. (FR) | 2004-05-13 | — | — | US | disclosed |
| EP-1363889-A1 | NOVEL DIAMINOPYRAZOLE DERIVATIVES AND THEIR USE FOR OXIDATION DYEING OF KERATINOUS FIBRES | L'OREAL (FR) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002066440-A1 | DIAMINOPYRAZOLE DERIVATIVES AND THEIR USE FOR OXIDATION DYEING OF KERATINOUS FIBRES | L'OREAL (FR) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040088802-A1 | Diaminopyrazole derivatives and their use for oxidation dyeing of keratinous fibres | CBR3, CBR1, CYB5R3 | SMPD3 4191/4885AOC3 15/4885CNR2 787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.